Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

References

• Thies W, Bleiler L; Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013;9(2):208-45
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Frisardi V, et al. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 2009;26(7):537-55
   Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
   PubMed Web of Science ®Google Scholar
• Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999;58(11):1147-55
   Google Scholar
• Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001;11(5):585-90
   Google Scholar
• Seubert P, Vigo-Pelfry C, Esch F, et al. Isolation and quantification of soluble Alzheimer's b-peptide from biological fluids. Nature 1996;359(6393):325-7
   Google Scholar
• Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Ab42(43) and Ab40 in senile plaques with specific Ab monoclonals: evidence that the initially deposited species is Ab42(43). Neuron 1993;13(1):45-53
   Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-8
   PubMed Web of Science ®Google Scholar
• Armstrong RA. The pathogenesis of Alzheimer's disease: a reevaluation of the “Amyloid Cascade Hypothesis”. Int J Alzheimers Dis 2011;630865
   Google Scholar
• Giasson BI, Lee VMY, Trojanowski JQ. Interactions of amyloidogenic proteins. Neuromolecular Med 2003;4(1-2):49-58
   PubMed Web of Science ®Google Scholar
• Smith MA, Siedlak SL, Richey PL, et al. Tau protein directly interacts with the amyloid β-protein precursor: implications for Alzheimer's disease. Nat Med 1995;1(4):365-9
   Google Scholar
• Oyama F, Shimada H, Oyama R, et al. β-amyloid protein precursor and τ mRNA levels versus β-amyloid plaque and neurofibrillary tangles in the aged human brain. J Neurochem 1993;60(5):1658-64
   Google Scholar
• Terry RD. Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol 2006;19(3):125-8
   Google Scholar
• Mc Donald JM, Savva GM, Brayne C, et al. Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010;133(Pt 5):1328-41
   Google Scholar
• Shankar GM, Li S, Mehta TH, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14(8):837-42
   PubMed Web of Science ®Google Scholar
• Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing 2013;10(1):18
   PubMed Web of Science ®Google Scholar
• Lesnè S, Koh MT, Kotilinek L, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006;440(7082):352-7
   PubMed Web of Science ®Google Scholar
• Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009;106(10):4012-17
   PubMed Web of Science ®Google Scholar
• Takashima A. TAU aggregation is a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2010;7(8):665-9
   Google Scholar
• Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42(3 Pt):631-9
   Google Scholar
• Panza F, Frisardi V, Solfrizzi V, et al. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 2012;4(2):213-38
   PubMed Web of Science ®Google Scholar
• Medina M. Recent developments in tau-based therapeutics for neurodegenerative diseases. Recent Pat CNS Drug Discov 2011;6(1):20-30
   PubMedGoogle Scholar
• Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2013;10(3):217-28
   Google Scholar
• Yoshiyama Y, Lee VM, Trojanowski JQ. Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2013;84(7):784-95
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong CX, et al. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009;118(1):53-69
   PubMed Web of Science ®Google Scholar
• Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8(10):783-93
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8(2):101-12
   PubMed Web of Science ®Google Scholar
• Corbett A, Smith J, Ballard C. New and emerging treatments for Alzheimer's disease. Expert Rev Neurother 2012;12(5):535-43
   PubMed Web of Science ®Google Scholar
• Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63(10):1459-67
   PubMedGoogle Scholar
• Asuni AA, Boutajangout A, Quartermain D, et al. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27(34):9115-29
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30(49):16559-66
   PubMed Web of Science ®Google Scholar
• Boimel M, Grigoriadis N, Lourbopoulos A, et al. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224(2):472-85
   PubMed Web of Science ®Google Scholar
• Bi M, Ittner A, Ke YD, et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011;6:e26860
   PubMed Web of Science ®Google Scholar
• Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012;9(4):397-405
   PubMed Web of Science ®Google Scholar
• Boutajangout A, Ingadottir J, Davies P, et al. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118(4):658-67
   PubMed Web of Science ®Google Scholar
• Chai X, Wu S, Murray TK, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011;286(39):34457-67
   PubMed Web of Science ®Google Scholar
• Axon Neuroscience SE. Safety study of AADvac1, a Tau Peptide-KLH-conjugate active vaccine to treat alzheimer's disease. ClinicalTrials.gov identifier NCT01850238. Available from: http://clinicaltrials.gov/ct2/show/NCT01850238?term=NCT01850238&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 2013;248(8):451-6
   Google Scholar
• Novak M. Tau vaccine: active immunization with misfloded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement 2009;5(Suppl 1):P93
   Google Scholar
• Li Y, Liu Y, Wang Z, Jiang Y. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Expert Opin Biol Ther 2013;13(11):1515-22
   PubMed Web of Science ®Google Scholar
• Sarazin M, Dorothée G, de Souza LC, Aucouturier P. Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle? Biol Psychiatry 2013;74(5):329-32
   PubMedGoogle Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400(6740):173-7
   PubMed Web of Science ®Google Scholar
• Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3(10):824-8
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64(1):94-101
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46-54
   PubMed Web of Science ®Google Scholar
• Ferrer I, Boada Rovira M, Sánchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14(1):11-20
   PubMed Web of Science ®Google Scholar
• Vellas B, Black R, Thal LJ, et al. AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6(2):144-51
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame A, et al. Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64(1):129-31
   Google Scholar
• Bombois S, Maurage CA, Gompel M, et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 2007;64(4):583-7
   PubMedGoogle Scholar
• Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62(11):1087-95
   Google Scholar
• Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 2008;372(9634):216-23
   PubMed Web of Science ®Google Scholar
• Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6(6):108-19
   Google Scholar
• Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Ab42 fibrils. Science 2001;293(5534):1491-5
   PubMed Web of Science ®Google Scholar
• Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43(3):321-32
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159(2):439-47
   Google Scholar
• Movsesyan N, Ghochikyan A, Mkrtichyan M, et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine – a novel immunotherapeutic strategy. PLoS One 2008;3(5):e2124
   Web of Science ®Google Scholar
• Movsesyan N, Mkrtichyan M, Petrushina I, et al. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol 2008;205(1-2):57-63
   PubMed Web of Science ®Google Scholar
• Li Y, Ma Y, Zong LX, et al. Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Aβ3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice. J Neuroimmunol 2012;249(1-2):16-26
   Google Scholar
• Frenkel D, Dewachter I, Van Leuven F, Solomon B. Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. Vaccine 2003;21(11-12):1060-5
   PubMed Web of Science ®Google Scholar
• Qu B, Rosenberg RN, Li L, et al. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 2004;61(12):1859-64
   Google Scholar
• Qu BX, Xiang Q, Li L, et al. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci 2007;260(1-2):204-13
   Google Scholar
• Okura Y, Miyakoshi A, Kohyama K, et al. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci USA 2006;103(25):9619-24
   Google Scholar
• Bach P, Tschäpe JA, Kopietz F, et al. Vaccination with Aβ-displaying virus-like particles reduces soluble and insoluble cerebral Aβ and lowers plaque burden in APP transgenic mice. J Immunol 2008;182(12):7613-24
   Google Scholar
• Matsumoto Y, Niimi N, Kohyama K. Development of a New DNA vaccine for Alzheimer disease targeting a wide range of Aβ species and amyloidogenic peptides. PLoS One 2013;8(9):e75203
   Google Scholar
• Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174(3):1580-6
   Google Scholar
• Petrushina I, Ghochikyan A, Mktrichyan M, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice. J Neurosci 2007;27(46):12721-31
   PubMed Web of Science ®Google Scholar
• Bowers WJ, Mastrangelo MA, Stanley HA, et al. HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigenspecific immune responses. Neurobiol Aging 2005;26(4):393-407
   Google Scholar
• Santuccione AC, Merlini M, Shetty A, et al. Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice. Mol Psychiatry 2013;18(3):358-68
   Google Scholar
• Carrera I, Etcheverría I, Fernández-Novoa L, et al. Vaccine development to treat Alzheimer's disease neuropathology in APP/PS1 transgenic mice. Int J Alzheimers Dis 2012;2012:376138
   Google Scholar
• Hara H, Monsonego A, Yuasa K, et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimers Dis 2004;6(5):483-8
   Google Scholar
• Mouri A, Noda Y, Hara H, et al. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007;21(9):2135-48
   Google Scholar
• Nojima J, Maeda A, Aoki S, et al. Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model. Vaccine 2011;29(37):6252-8
   PubMed Web of Science ®Google Scholar
• Davtyan H, Ghochikyan A, Petrushina I, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 2013;33(11):4923-34
   PubMed Web of Science ®Google Scholar
• Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31(25):9323-31
   PubMed Web of Science ®Google Scholar
• Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11(7):597-604
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Safety, tolerability and abeta-specific antibody response of repeated i.m. injections of adjuvanted CAD106 in mild alzheimer patients. ClinicalTrials.gov identifier NCT01097096. Available from: http://clinicaltrials.gov/ct2/show/NCT01097096?term=CAD106&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Novartis. To investigate the safety and tolerability of repeated subcutaneous injections of CAD106 in alzheimer's patients. ClinicalTrials.gov NCT00956410. Available from: http://clinicaltrials.gov/ct2/show/NCT00956410?term=CAD106&rank=2 [Last accessed 26 November 2013]
   Google Scholar
• Novartis. safety and tolerability of repeated subcutaneous injections of CAD 106 in mild alzheimer's patients. ClinicalTrials.gov NCT00795418. Available from: http://clinicaltrials.gov/ct2/show/NCT00795418?term=CAD106&rank=3 [Last accessed 26 November 2013]
   Google Scholar
• Novartis. To investigate the safety and tolerability of repeated subcutaneous injections of CAD106 in alzheimer's patients. ClinicalTrials.gov NCT01023685. Available from: http://clinicaltrials.gov/ct2/show/NCT01023685?term=CAD106&rank=4 [Last accessed 26 November 2013]
   Google Scholar
• Novartis. Safety and tolerability of repeated subcutaneous injections of CAD106 in mild alzheimer's patients. ClinicalTrials.gov NCT00733863. Available from: http://clinicaltrials.gov/ct2/show/NCT00733863?term=CAD106&rank=6 [Last accessed 26 November 2013]
   Google Scholar
• Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 2009;17(2):243
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Otawa O, et al. Development of AFFITOPE vaccines for Alzheimer's disease (AD) - from concept to clinical testing. J Nutr Health Aging 2009;13(3):264-7
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013;15(84):319-26
   Google Scholar
• Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013;8(1):36
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6(8):916-19
   PubMed Web of Science ®Google Scholar
• Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis 2005;2(5):261-6
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Imbimbo BP, et al. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res 2011;8(8):808-17
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 2012;8(2):135-49
   PubMed Web of Science ®Google Scholar
• Tayeb HO, Murray ED, Price BH, Tarazi FI. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013;13(7):1075-84
   PubMed Web of Science ®Google Scholar
• Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7(4):367-85
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24):2061-70
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H, Rinne JO, et al. AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012;69(8):1002-10
   PubMedGoogle Scholar
• Pfizer and JANSSEN alzheimer immunotherapy research & development, LLC. Study evaluating the safety Of AAB-003 (PF-05236812) in subjects with alzheimer's disease. ClinicalTrials.gov identifier NCT01193608. Available from: http://clinicaltrials.gov/ct2/show/NCT01193608?term=NCT01193608&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Pfizer and JANSSEN alzheimer immunotherapy research & development, LLC. Open label extension study evaluating safety and tolerability of AAB-003 (PF-05236812) in subject with mild to moderate alzheimer's disease. ClinicalTrials.gov identifier NCT01369225. Available from: http://clinicaltrials.gov/ct2/show/NCT01369225?term=NCT01369225&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Seubert P, Barbour R, Khan K, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5(2):65-71
   PubMed Web of Science ®Google Scholar
• Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012;8(4):261-71
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33(2):67-73
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Effect of LY2062430 on the progression of alzheimer's disease (EXPEDITION). ClinicalTrials.gov identifier: NCT00905372. Available from: http://clinicaltrials.gov/ct2/show/NCT00905372?term=NCT00905372&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Eli Lilly and Company. Effect of LY2062430 on the progression of alzheimer's disease (EXPEDITION2). ClinicalTrials.gov identifier NCT00904683. Available from: http://clinicaltrials.gov/ct2/show/NCT00904683?term=NCT00904683&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Eli Lilly and Company. Continued safety monitoring of solanezumab in alzheimer's disease (EXPEDITION EXT). ClinicalTrials.gov identifier NCT01127633. Available from: http://clinicaltrials.gov/ct2/show/NCT01127633?term=NCT00905372&rank=2 [Last accessed 26 November 2013]
   Google Scholar
• Washington University School of Medicine with Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), and Avid Radiopharmaceuticals. Dominantly Inherited Alzheimer Network Trial: An opportunity to prevent dementia. a study of potential disease modifying treatments in individuals at risk for or with a type of early onset alzheimer's disease caused by a genetic mutation. (DIAN TU). ClinicalTrials.gov NCT01760005. Available from: http://clinicaltrials.gov/ct2/show/NCT01760005?term=NCT01760005&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Eli Lilly and Company. Progress of mild alzheimer's disease in participants on solanezumab versus placebo (EXPEDITION3). ClinicalTrials.gov identifier NCT01900665. Available from: http://clinicaltrials.gov/ct2/show/NCT01900665?term=NCT01900665&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Yamada K, Yabuki C, Seubert P, et al. Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. J Neurosci 2009;29(36):11393-8
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98(15):8850-5
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295(5563):2264-7
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367(9):795-804
   PubMed Web of Science ®Google Scholar
• Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12(4):357-67
   PubMed Web of Science ®Google Scholar
• Miller G. News focus: stopping Alzheimer's before it starts. Science 2012;337(6096):790-2
   PubMedGoogle Scholar
• Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330(6012):1774
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6(8):734-46
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9(11):1118-27
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 2012;28(1):49-69
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69(2):198-207
   PubMedGoogle Scholar
• Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther 2012;12(8):1077-86
   PubMed Web of Science ®Google Scholar
• Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin Investig 2012;2(10):975-84
   PubMedGoogle Scholar
• GlaxoSmithKline. A clinical study to assess single and repeat doses of a new medication (GSK933776) in patients with alzheimer's disease. ClinicalTrials.gov identifier NCT00459550. Available from: http://clinicaltrials.gov/ct2/show/NCT00459550?term=NCT00459550&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• GlaxoSmithKline. Modulation of Abeta Levels by GSK933776 in alzheimer's disease patient. ClinicalTrials.gov identifier NCT01424436. Available from: http://clinicaltrials.gov/ct2/show/NCT01424436?term=NCT01424436&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Freeman GB, Lin JC, Pons J, Raha NM. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis 2012;28(3):531-41
   Google Scholar
• Burstein AH, Zhao Q, Ross J, et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol 2013;36(1):8-13
   Google Scholar
• Landen JW, Zhao Q, Cohen S, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 2013;36(1):14-23
   Google Scholar
• Pfizer. A Multiple Dose Study of PF-04360365 In patients with mild to moderate alzheimer's disease. ClinicalTrials.gov identifier NCT00945672. Available from: http://clinicaltrials.gov/ct2/show/NCT00945672?term=NCT00945672&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Pfizer. Multiple IV Dose Study Of PF-04360365 in patients with mild to moderate alzheimer's disease. ClinicalTrials.gov identifier NCT00722046. Available from: http://clinicaltrials.gov/ct2/show/NCT00722046?term=NCT00722046&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 2012;32(28):9677-89
   PubMed Web of Science ®Google Scholar
• Garber K. Genentech's Alzheimer's antibody trial to study disease prevention. Nat Biotechnol 2012;30(8):731-2
   Google Scholar
• Genentech. A long-term safety extension study of studies ABE4869g and ABE4955g in patients with mild to moderate alzheimer's disease treated with crenezumab. ClinicalTrials.gov identifier NCT01723826. Available from: http://clinicaltrials.gov/ct2/show/NCT01723826?term=NCT01723826&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Lemere CA, Lopera F, Kosik KS, et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 1996;2(10):1146-50
   PubMed Web of Science ®Google Scholar
• Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277(10):793-9
   PubMed Web of Science ®Google Scholar
• Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(Suppl 3):321-9
   PubMed Web of Science ®Google Scholar
• Eisai Inc. A randomized, double-blind, placebo-controlled, combined single ascending dose and multiple ascending dose study. ClinicalTrials.gov identifier NCT01230853. Available from: http://clinicaltrials.gov/ct2/show/NCT01230853?term=NCT01230853&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Eisai Inc. A study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early alzheimer's disease. ClinicalTrials.gov identifier NCT01767311. Available from: http://clinicaltrials.gov/ct2/show/NCT01900665?term=NCT01900665&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Biogen Idec. Single ascending dose study of BIIB037 in subjects with alzheimer's disease. ClinicalTrials.gov identifier NCT01397539. Available from: http://clinicaltrials.gov/ct2/show/NCT01397539?term=NCT01397539&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Biogen Idec. Multiple dose study of BIIB037 in subjects with prodromal or mild alzheimer's disease. ClinicalTrials.gov identifier NCT01677572. Available from: http://clinicaltrials.gov/ct2/show/NCT01677572?term=NCT01677572&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Sanofi. Single and repeated dosing study to assess the safety and the concentration-time profile of SAR228810 in alzheimer's patients. ClinicalTrials.gov identifier NCT01485302. Available from: http://clinicaltrials.gov/ct2/show/NCT01485302?term=SAR228810&rank= [Last accessed 26 November 2013]
   Google Scholar
• Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimer's disease. Expert Opin Biol Ther 2011;11(3):343-57
   PubMed Web of Science ®Google Scholar
• Loeffler DA. Intraveneous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013;10(1):70
   PubMedGoogle Scholar
• Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12(3):233-43
   PubMedGoogle Scholar
• Baxter Healthcare Corporation. A Phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild-to-moderate alzheimer´s disease. ClinicalTrials.gov identifier NCT00818662. Available from: http://clinicaltrials.gov/ct2/show/NCT00818662?term=NCT00818662&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• Magga J, Puli L, Pihlaja R, et al. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010;7:90
   Google Scholar
• Sutter health. Study of intravenous immunoglobulin in amnestic mild cognitive impairment (MCI). ClinicalTrials.gov identifier NCT01300728. Available from: http://clinicaltrials.gov/ct2/show/NCT01300728?term=NCT01300728&rank= [Last accessed 26 November 2013]
   Google Scholar
• Instituto Grifols, S.A. A Study to evaluate albumin and immunoglobulin in alzheimer's disease (AMBAR). ClinicalTrials.gov identifier NCT01561053. Available from: http://clinicaltrials.gov/ct2/show/NCT01561053?term=NCT01561053&rank=1 [Last accessed 26 November 2013]
   Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease. Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-9
   PubMed Web of Science ®Google Scholar
• Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease. Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270-9
   PubMed Web of Science ®Google Scholar
• Goodger ZV, Rajendran L, Trutzel A, et al. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci 2009;122(Pt 20):3703-14
   Google Scholar
• Belyaev ND, Kellett KA, Beckett C, et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a beta-secretase-dependent pathway. J Biol Chem 2010;285(53):41443-54
   Google Scholar
• Ghosal K, Vogt DL, Liang M, et al. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 2009;106(43):18367-72
   Google Scholar
• Buoso E, Lanni C, Schettini G, et al. beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol Res 2010;62(4):308-17
   Google Scholar
• Konietzko U. AICD nuclear signaling and its possible contribution to Alzheimer's disease. Curr Alzheimer Res 2012;9(2):200-16
   Google Scholar
• Kimberly WT, Zheng JB, Guénette SY, Selkoe DJ. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 2001;276(43):40288-92
   Google Scholar
• Kinoshita A, Whelan CM, Smith CJ, et al. Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J Neurochem 2002;82(4):839-47
   Google Scholar
• Beckett C, Nalivaeva NN, Belyaev ND, Turner AJ. Nuclear signalling by membrane protein intracellular domains: the AICD enigma. Cell Signal 2012;24(2):402-9
   Google Scholar
• Ghosal K, Stathopoulos A, Pimplikar SW. APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 2010;5(7):e11866
   PubMed Web of Science ®Google Scholar
• Passer B, Pellegrini L, Russo C, et al. Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis 2000;2(3-4):289-301
   Google Scholar
• Müller T, Meyer HE, Egensperger R, Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol 2008;85(4):393-406
   Google Scholar
• Pardossi-Piquard R, Checler F. The physiology of the beta-amyloid precursor protein intracellular domain AICD. J Neurochem 2012;120(Suppl 1):109-24
   Google Scholar
• Kinoshita A, Whelan CM, Berezovska O, Hyman BT. The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 2002;277(32):28530-6
   Google Scholar
• Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem 2006;281(7):4292-9
   PubMed Web of Science ®Google Scholar
• Lambert MP, Velasco PT, Chang L, et al. Monoclonal antibodies that target pathological assemblies of Aβ. J Neurochem 2007;100(1):23-35
   PubMed Web of Science ®Google Scholar
• Frost JL, Liu B, Kleinschmidt M, et al. Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer's-like transgenic mice: a pilot study. Neurodegenerative Dis 2012;10(1-4):265-70
   PubMed Web of Science ®Google Scholar
• Kim J, Eltorai AE, Jiang H, et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. J Exp Med 2012;209(12):2149-56
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 2012;76(5):908-20
   PubMed Web of Science ®Google Scholar
• Morales-Corraliza J, Schmidt SD, Mazzella MJ, et al. Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. Neurobiol Aging 2013;34(1):137-45
   PubMed Web of Science ®Google Scholar
• Gandy S, Haroutunian V, DeKosky ST, et al. CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease. Biol Psychiatry 2013;73(5):393-5
   Google Scholar
• Neumann H, Daly MJ. Variant TREM2 as risk factor for Alzheimer's disease. N Engl J Med 2013;368(2):182-4
   Web of Science ®Google Scholar
• Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013;78(4):631-43
   PubMed Web of Science ®Google Scholar
• Thambisetty M, An Y, Nalls M, et al. Baltimore Longitudinal Study of Aging and the Alzheimer's Disease Neuroimaging Initiative. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 2013;73(1):422-8
   Google Scholar